Vogel M, Boesecke C, Wasmuth J-C, Rockstroh J K
Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn.
Dtsch Med Wochenschr. 2010 Jun;135(23):1186-91. doi: 10.1055/s-0030-1255129. Epub 2010 May 31.
Chronic hepatitis C virus (HCV) infection is currently one of the most clinically relevant co-morbidities in the HIV-infected population. Overall, one third of HIV-infected individuals in Europe are HCV co-infected. The progression of chronic HCV infection to liver cirrhosis with subsequent risk for liver decompensation and hepatocellular carcinoma is substantially accelerated in HIV/HCV co-infected compared to HCV mono-infected individuals, particularly with advanced levels of immunodeficiency. Indeed, immune reconstitution under HAART has been associated with slowing down fibrosis progression in HIV/HCV co-infected individuals. Therefore HAART initiation is recommended earlier in HCV co-infected patients. Moreover, the sequelae of chronic hepatitis C infection can be stopped by successful treatment with pegylated interferon and ribavirin combination therapy so that every HIV/HCV co-infected patient should be evaluated for possible HCV treatment. - In this review we summarize the current epidemiology, natural course of HCV in HIV co-infection and current guidelines for management of chronic hepatitis C infection in HIV co-infected patients.
慢性丙型肝炎病毒(HCV)感染是目前HIV感染人群中临床上最相关的合并症之一。总体而言,欧洲三分之一的HIV感染者合并感染HCV。与单纯HCV感染个体相比,HIV/HCV合并感染个体中慢性HCV感染进展为肝硬化并随后出现肝失代偿和肝细胞癌的风险显著加快,尤其是在免疫缺陷程度较高的情况下。事实上,高效抗逆转录病毒治疗(HAART)下的免疫重建与减缓HIV/HCV合并感染个体的纤维化进展有关。因此,建议在HCV合并感染患者中更早开始HAART。此外,聚乙二醇化干扰素和利巴韦林联合治疗成功可阻止慢性丙型肝炎感染的后遗症,因此每个HIV/HCV合并感染患者都应评估是否可能进行HCV治疗。——在本综述中,我们总结了目前的流行病学、HIV合并感染中HCV的自然病程以及HIV合并感染患者慢性丙型肝炎感染的当前管理指南。